The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with $63.6 billion in annual revenue and an impressive 74% gross profit margin, has announced the U.S. Food and Drug Administration's ...

(The Guardian) The FDA expanded indications for brentuximab vedotin (Adcetris) to include use in combination therapy for relapsed/refractory large B-cell lymphoma that has progressed on at least two ...

The Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) in combination with Revlimid (lenalidomide) and Rituxan (rituximab) for the treatment of adults with relapsed or ...

In her budget speech, Finance Minister Nirmala Sitharaman announced the exemption of 36 drugs used to treat cancer, rare ...

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

Moreover, Ryoncil is not definitively preferred over other options after ruxolitinib, such as mycophenolate, sirolimus, and brentuximab vedotin. How preferred Ryoncil is will probably depend on ...